More Company News

HUTCHMED

Fruquintinib clinical data at 2022 ASCO GI Cancers Symposium
19 Jan 2022Read More

HUTCHMED

BTD in China for HMPL-523 in primary ITP
12 Jan 2022Read More

HUTCHMED

Initiation of China Phase I of BTK inhibitor HMPL-760 in B-cell NHL
10 Jan 2022Read More

HUTCHMED

Highlighted HMPL-523 clinical data at ASH 2021
14 Dec 2021Read More

HUTCHMED

Highlighted Surufatinib and Toripalimab combination clinical data at ESMO Immuno-Oncology 2021
10 Dec 2021Read More

HUTCHMED

Completion of enrolment in global FRESCO-2 Phase III of fruquintinib in mCRC
06 Dec 2021Read More

HUTCHMED

Continued inclusion of Elunate and addition of Sulanda to China NRDL
03 Dec 2021Read More

HUTCHMED

Initiation of SACHI China Phase III trial
24 Nov 2021Read More

HUTCHMED

Initiation of SAMETA Global Phase III trial
01 Nov 2021Read More

HUTCHMED

Initiation of ESLIM-01 China Phase III trial in ITP
28 Oct 2021Read More

1 2 3 4 5 … 12
Return to HUTCHMED
© 2019-22 Trinity Delta. All rights reserved. Trinity Delta is regulated by the Financial Conduct Authority (Reference number: 725161).